You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Moodys
Express Scripts
Merck
Mallinckrodt

Last Updated: June 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EPLERENONE

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Eplerenone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00082589 The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure Completed Pfizer Phase 4 2004-04-01 The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
NCT00094302 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2006-08-01 The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.
NCT00094302 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function Completed New England Research Institutes Phase 3 2006-08-01 The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.
NCT00108251 Aldosterone Antagonism in Diastolic Heart Failure Completed VA Office of Research and Development Phase 4 2004-08-01 The primary purpose of this study is to determine whether eplerenone has a beneficial effect on improving exercise ability in patients with diastolic heart failure.
NCT00132093 Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack Completed NHS Greater Glasgow and Clyde Phase 4 2005-04-01 The purpose of this study is to ascertain whether treatment with the drug eplerenone, taken early after a heart attack, prevents or reduces some of the adverse changes that may otherwise naturally occur within the heart muscle, that lead ultimately to weakening of the heart muscle and premature death.
NCT00138944 Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension Completed University of Erlangen-Nürnberg Medical School Phase 3 2007-01-01 Resistant hypertension is defined as hypertension not controlled (i.e. blood pressure not below 140/90 mmHg) with the use of adequate doses of at least three different anti-hypertensives including a diuretic. Resistant hypertension is abundant. In the ALLHAT trial 34% of patients did not reach the blood pressure goal of 140/90 mmHg. One possible mechanism of resistance is the aldosterone-escape phenomenon. During aldosterone escape, aldosterone plasma levels are normal or even elevated despite therapy with ACEIs or ARBs. The prevalence is about 30-50%. Possible reasons for aldosterone escape are alternative ways of aldosterone stimulation (hyperkalemia, adrenomedullin, ACTH), local aldosterone production or primary aldosteronism. Aldosterone has deleterious blood pressure independent effects on cardiac, vascular and renal damage. Hypothesis: Eplerenone is effective to improve hypertensive target organ damage in patients with resistant hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eplerenone

Condition Name

Condition Name for Eplerenone
Intervention Trials
Hypertension 21
Heart Failure 10
Central Serous Chorioretinopathy 4
Chronic Kidney Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Eplerenone
Intervention Trials
Hypertension 22
Heart Failure 19
Renal Insufficiency, Chronic 8
Kidney Diseases 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Eplerenone

Trials by Country

Trials by Country for Eplerenone
Location Trials
United States 183
Japan 45
Canada 27
United Kingdom 17
Germany 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Eplerenone
Location Trials
Massachusetts 12
Ohio 11
Tennessee 10
California 9
Texas 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Eplerenone

Clinical Trial Phase

Clinical Trial Phase for Eplerenone
Clinical Trial Phase Trials
Phase 4 32
Phase 3 14
Phase 2/Phase 3 5
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Eplerenone
Clinical Trial Phase Trials
Completed 45
Recruiting 23
Not yet recruiting 18
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Eplerenone

Sponsor Name

Sponsor Name for Eplerenone
Sponsor Trials
Pfizer 17
Brigham and Women's Hospital 9
Radboud University 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Eplerenone
Sponsor Trials
Other 126
Industry 37
NIH 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Colorcon
Express Scripts
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.